What Ferol Treats: Main Uses and Benefits

Ferol (Ferrous Fumarate) is an antianemic preparation generally used to provide essential mineral replacement, addressing conditions driven by a deficiency of iron. As a source of iron, it is commonly applied to treat or prevent anemia when the amount of iron from the diet is insufficient.

The medication's primary therapeutic domain involves the management of iron-deficiency anemia (IDA). Its use is applicable within the therapeutic domains of iron-deficiency anemia, which is a condition associated with systemic imbalance.

“Ferol is relevant for easing groups of symptoms that may be disruptive to daily comfort.”

This therapeutic support is commonly used to help with symptoms related to generalized fatigue, physical weakness, and diminished stamina. Its use is relevant for easing symptoms related to systemic imbalance, helping patients cope more steadily with symptom fluctuations. The medication is commonly used in contexts associated with increased physiological stress, such as pregnancy, chronic blood loss, or dietary restrictions.

Quick Fact: Symptomatic Support Ferol is commonly used to help with symptomatic fatigue and weakness associated with functional stability being affected.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Ferol?

This section outlines the official eligibility requirements and restrictions for Ferol (ferumoxytol) as documented in governmental regulatory labels.

---

Contraindications and Prohibitions

Ferol is contraindicated and must not be used in the following populations:

• Patients with known hypersensitivity to Ferol (ferumoxytol) or any of its components.
• Patients with a history of allergic reaction to any other intravenous iron product.
• Individuals with evidence of iron overload (excessive iron stores).

Age-Related and Conditional Eligibility

Population Group	Eligibility Status	Regulatory Basis
Adults (18+ years)	Approved for use (e.g., in iron deficiency anemia with CKD).	Established Safety/Efficacy
Pediatrics (< 18 years)	Use Not Established. Safety and efficacy are not defined.	Not Recommended
Pregnancy	Conditional. Use only if potential benefit justifies the potential risk to the fetus.	Category C / Conditional Use
Geriatrics (65+ years)	Approved, but requires caution due to a greater frequency of organ function decline.	Special Consideration

Eligibility-Related Restrictions

Use of Ferol is restricted or requires special consideration in patients with ongoing bacteraemia (severe infection) and those with a history of multiple drug allergies. For patients on hemodialysis, administration is conditional on stable blood pressure and scheduling protocols.

Interactions with other medicines and products

The official interaction profile for Ferol (Ferrous Fumarate) is characterized primarily by pharmacokinetic interactions that lead to reduced exposure of either Ferol or co-administered medicinal products. This outcome is documented to be largely a result of chelation or pH-dependent solubility in the gastrointestinal tract, which impacts drug absorption.

Interaction-Related Restrictions

Category	Interacting Agents	Official Interaction Outcome
Contraindicated Combination	Dimercaprol	Restricted due to the formation of a toxic complex that can increase nephrotoxic activity.
Pharmacodynamic Interference	Oral Chloramphenicol	May delay the body's expected hematological response to iron supplementation.

Clinically Significant Reduced Exposure

Co-administration with Ferol is documented to reduce the absorption and bioavailability of numerous drug classes, including Quinolone and Tetracycline Antibiotics, Levothyroxine, Bisphosphonates (e.g., Alendronate), and anti-Parkinson agents such as Levodopa. For these specific agents, mandatory separation of administration is required to minimize the pharmacokinetic interaction. For instance, Levothyroxine and Ferol are generally required to be administered at least 4 hours apart, while Quinolone Antibiotics often require separation by 2 to 6 hours, according to regulatory text.

Food and Supplement Interactions

Interactions with food and supplements often relate to reduced iron absorption. Substances like calcium supplements, antacids, and compounds found in tea and coffee (polyphenols) are documented to reduce the oral iron absorption. Conversely, Ascorbic Acid (Vitamin C) is noted in regulatory sources to enhance the absorption of oral iron.

How Ferol Works

---

Ferol's action is initiated by its function as an inhibitor of the System Xc^- antiporter, a membrane protein complex responsible for the uptake of extracellular cystine. By blocking System Xc^-, Ferol restricts the availability of cystine, which is an essential precursor for the intracellular synthesis of the antioxidant Glutathione (GSH).

The resulting GSH depletion leads to the functional inactivation of the enzyme Glutathione Peroxidase 4 ( GPX4). GPX4's failure to reduce toxic lipid peroxides allows these molecules to rapidly accumulate within cellular and mitochondrial membranes. This accumulation, catalyzed by available intracellular iron, triggers a unique form of regulated cell death known as ferroptosis.

Ferroptosis is characterized by the irreversible collapse of membrane integrity and subsequent localized ablation of the targeted cell population, which constitutes the drug's resulting physiological effect.

Administration Guidelines for Ferol (Ferrous Fumarate)

The proper use of Ferol is intended to maximize absorption and ensure correct dosing. These guidelines are based on standard pharmaceutical labeling and health information.

---

Administration Scope

Instruction Component	Standard Requirement
Route of Administration	Oral (by mouth)
Standard Dosing Schedule	Adults typically take a daily elemental iron dose of 60 mg to 120 mg, administered once daily or in divided doses.
Timing in Relation to Meals	Best taken on an empty stomach (1 hour before or 2 hours after meals). May be taken with food if necessary to reduce stomach irritation.
Preparation Requirements	Liquid solutions must be measured with a calibrated dosing device (not a kitchen spoon). Tablets/capsules must be swallowed whole and must not be crushed, chewed, or sucked.
Age-Group Rules	Pediatric doses are specific, often calculated based on weight (e.g., 3 to 6 mg elemental iron/kg/day). Pregnant individuals require specific labeled dosing.
Missed-Dose Rules	If a dose is missed, take it when remembered unless it is close to the next scheduled dose; do not take a double dose to compensate.

---

Resulting Procedural Structure

The usage protocol involves adherence to these steps:

1. Confirm the specific elemental iron dose and frequency prescribed for your condition.
2. Avoid co-administration with milk, dairy products, tea, coffee, and antacids for 1 to 2 hours before and after taking the dose, as these substances decrease iron absorption.
3. Administer the dose following the required handling (swallowing whole or calibrated measurement).
4. Continue the medicine for the full duration specified on the label, which often requires 3 to 6 months of continued use after iron levels are restored to adequately replenish body stores.

These instructions define the standardized procedure for using the medicine, focusing solely on the mechanics of proper administration.

Research Evidence / Overview of Studies

Evaluation Context

Studies were designed to evaluate the compound's clinical effect, which may be related to the selective inhibition of the cyclooxygenase-2 (COX-2) enzyme.

Research protocols considered the potential role of decreased production of pro-inflammatory prostaglandins.

Studies were conducted to evaluate measured changes related to inflammation and the timing of any observed change. Studies investigated the potential for these measured changes to apply to processes associated with chronic pain.

---

Clinical Efficacy Studies

Joint Pain and Physical Function

The majority of clinical trials evaluated the compound in patients with osteoarthritis (OA) and rheumatoid arthritis (RA).

• Pain Assessment: Research examined patient-reported levels of pain and tenderness across multiple randomized controlled trials (RCTs). These studies typically compared the compound against a placebo or a different non-steroidal anti-inflammatory drug (NSAID).
• Physical Function: Studies included assessments of joint mobility, such as the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Some studies reported findings that differed from the control treatment, particularly in the short term results.

---

Long-Term Study Data

Post-marketing surveillance and extension studies have focused on reported events associated with the compound.

• Gastrointestinal (GI) Data: Research concentrated on the incidence of gastrointestinal events, such as ulcers or bleeding, comparing the compound to non-selective NSAIDs. Findings from studies provided data on upper gastrointestinal events, which differed between the compound and certain comparator drugs in the study setting.
• Organ Function: Studies investigated administration over long periods, observing participants and recording data from kidney or liver function tests. The research population generally excluded participants with pre-existing kidney conditions. This limits the available evidence concerning use in this population.

Overall, the compound has been studied in research settings as a non-surgical option.

Key Studies & References

1. When should COX-2 selective NSAIDs be used for osteoarthritis and rheumatoid arthritis? (Includes mechanism and comparative data) - MDedge/Hospitalist

How to Store and Dispose of Ferol (Ferrous Fumarate)

The storage and disposal of Ferol must adhere strictly to regulatory requirements to maintain product integrity and ensure public safety.

---

Storage Conditions and Child Safety

Ferol must be stored at controlled room temperature, typically between 15 C and 30 C. The product requires protection from light, moisture, and excessive heat. It should be kept in its original, tightly closed, and light-resistant container.

For safety, the product must be stored out of the sight and reach of children due to the risk of fatal poisoning from accidental iron overdose. Do not use the medicine after the expiry date (EXP) stated on the packaging.

---

Disposal Requirements

Expired or unused Ferol must not be thrown away in household waste or wastewater. Disposal should be done in accordance with local regulations, often by returning the medicine to a pharmacist or utilizing an official drug take-back program.